Skip to main content

Treatment Clinical Trials for Small Cell Lung Cancer

Review the small cell lung cancer treatment clinical trials on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 76-99 of 99

A Study of BL-M14D1 in Patients With Locally Advanced or Metastatic Small Cell Lung Cancer, Neuroendocrine Tumors and Other Solid Tumors
Status: Active
Location: Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia
[212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors
Status: Active
Location: Siteman Cancer Center at Washington University, Saint Louis, Missouri
A Study of ZN-c3 in Participants With Solid Tumors
Status: Active
Location: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania
A Study of NPX887 for Participants With Solid Tumors Known to Express B7-H7/HHLA2
Status: Active
Location: Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland
A Study of MGC026 in Participants With Advanced Solid Tumors
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Personalized Radiation Therapy (PULSAR) for the Treatment of Patients with Extensive-Stage Small Cell Lung Cancer or Brain Metastases, the PRISM Trial
Status: Active
Location: UT Southwestern/Simmons Cancer Center-Dallas, Dallas, Texas
Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC)
Status: Active
Location: See ClinicalTrials.gov
A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)
Status: Active
Location: See ClinicalTrials.gov
A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
A Study of Orally Administered JBI-802, an LSD1/HDAC6 Inhibitor, in Patients With Advanced Solid Tumors
Status: Active
Location: See ClinicalTrials.gov
Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors
Status: Active
Location: Case Comprehensive Cancer Center, Cleveland, Ohio
Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067
Status: Active
Location: See ClinicalTrials.gov
Study of IBI3009 in Participants with Unresectable, Metastatic or Extensive-Stage Small Cell Lung Cancer
Status: Active
Location: UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California
DAREON™-9: A Study to Test How Well Different Doses of BI 764532 Are Tolerated by People With Small Cell Lung Cancer When Taken Together With a Single Agent Chemotherapy
Status: Active
Location: See ClinicalTrials.gov
A Study Evaluating MM-310 in Patients With Solid Tumors
Status: Active
Location: See ClinicalTrials.gov
A Phase 1 Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 in Advanced Solid Tumors
Status: Active
Location: See ClinicalTrials.gov
A Study of PSB205 in Subjects With Advanced Solid Tumors
Status: Active
Location: See ClinicalTrials.gov
A Study of DF6002 Alone and in Combination With Nivolumab
Status: Active
Location: See ClinicalTrials.gov
MOnaliZumab in Combination With durvAlumab (MEDI4736) Plus Platinum-based chemotheRapy for First-line Treatment of Extensive Stage Small Cell Lung Cancer
Status: Temporarily Closed to Accrual
Location: 3 locations
Niraparib and Dostarlimab for the Treatment of Small Cell Lung Cancer and Other High-Grade Neuroendocrine Carcinomas
Status: Temporarily Closed to Accrual
Location: M D Anderson Cancer Center, Houston, Texas
Vudalimab for the Treatment of Advanced Rare Cancers
Status: Temporarily Closed to Accrual
Location: M D Anderson Cancer Center, Houston, Texas
Stereotactic Body Radiotherapy in Combination with Durvalumab, Cisplatin or Carboplatin, and Etoposide for Treatment of Refractory Extensive Stage Small Cell Lung Cancer
Status: Temporarily Closed to Accrual
Location: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania
A Phase 1 Study Evaluating the Safety, Tolerability and Efficacy of AMG 119 in Subjects With RR SCLC
Status: Temporarily Closed to Accrual
Location: See ClinicalTrials.gov